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Abstract 
BACKGROUND AND PURPOSE: 
Lymphangiogenesis is an important biological process associated with the pathogenesis of 
several diseases, including metastatic dissemination, graft rejection, lymphedema and other 
inflammatory disorders. The development of new drugs blocking lymphangiogenesis has 
become a promising therapeutic strategy. In this study, we aim at investigating the ability of 
toluquinol, a 2-methyl-hydroquinone isolated from the culture broth of the marine fungus 
Penicillium sp. HL-85-ALS5-R004, to inhibit lymphangiogenesis in vitro, ex vivo and in vivo. 
EXPERIMENTAL APPROACH:  
We used human lymphatic endothelial cells (LEC) to analyze the effect of toluquinol in 2D 
and 3D in vitro cultures, and in the ex vivo mouse lymphatic ring assay. For in vivo 
approaches, the transgenic Fli1:eGFPy1 zebrafish, the mouse ear sponges and cornea models 
were used. Western-blotting and apoptosis analyses were carried out to search for drug 
targets. 
KEY RESULTS:  
Toluquinol inhibited LEC proliferation, migration, tubulogenesis and sprouting of new 
lymphatic vessels. Furthermore, toluquinol induced LEC apoptosis after 14 h of treatment in 
vitro, blocked the thoracic duct development in zebrafish, and reduced the VEGF-C-induced 
lymphatic vessel formation and corneal neovascularization in mice. Mechanistically, we are 
providing evidence that this drug abrogates the VEGF-C-induced VEGFR-3 phosphorylation 
in a dose-dependent manner, and represses Akt and ERK1/2 phosphorylations. 
CONCLUSIONS AND IMPLICATIONS:  
Based on these findings, we propose toluquinol as a new candidate with pharmacological 
potential for the treatment of lymphangiogenesis-related pathologies. Notably, its ability to 
suppress corneal neovascularization paves the way for applications in vascular ocular 
pathologies. 
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NON-STANDARD ABBREVIATIONS  
BAEC, bovine aortic endothelial cells; dpf, days post-fertilization; hpf, hours post-
fertilization; LEC, lymphatic endothelial cell; LYVE-1, lymphatic vessel endothelial 
hyaluronan receptor-1; MAPK, mitogen-activated protein kinase; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OCT, optimal cutting temperature; 
TBST, Tris buffered saline-Tween 20; RIPA, Radio-Immunoprecipitation Assay; VEGFR, 
vascular endothelial growth factor receptor. 
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INTRODUCTION 
The lymphatic vascular system constitutes a highly specialized part of the vascular system 
composed of a network of organs, lymph nodes, lymph ducts, and thin-walled and low 
pressure lymphatic vessels (Coso S et al., 2014). This vasculature is present in all regions of 
the human body with the exception of the bone marrow, the central nervous system, the 
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cornea, the retina, and tissues, such as the epidermis or the cartilage (Schulte-Merker et al., 
2011). The vital role of the lymphatic system is the maintenance of interstitial fluid 
homeostasis by absorbing water and macromolecules from the interstitium and transporting 
them back to the bloodstream. It is also essential for the intestinal dietary fat and vitamin 
absorption and is required for the trafficking of immune cells and immune surveillance 
(Tammela and Alitalo, 2010; Zheng et al., 2014). Taking into account the importance of 
lymphatic vessels for normal physiological functions, it is not surprising that abnormalities of 
the lymphatic vasculature are involved in several human pathologies.  
Lymphangiogenesis or the formation of new lymphatic vessels from preexisting ones is the 
major mode of lymphatic growth. This process is very active during the embryonic 
development but is uncommon in adulthood and frequently associated with pathological 
conditions. Defects in lymphatic function can lead to lymph and fat deposition in tissues, 
impaired immune responses and tissue swelling, known as lymphedema. In sharp contrast, an 
excessive lymphangiogenesis is crucially involved in various chronic inflammatory situations 
and graft rejection (Alitalo, 2011; Paupert et al., 2011; Karaman and Detmar, 2014). It is also 
well accepted that the lymphatic vasculature serves as a major route for tumor metastasis and 
that lymphangiogenesis contributes to cancer cell spreading from primary sites to lymph 
nodes (Zhang and Lu, 2014). Besides its pivotal implication in metastatic dissemination, 
lymphangiogenesis plays a key role in ocular pathologies and corneal graft rejection, where 
the neovascularization can provoke blindness (Abdelfattah et al., 2015).  
Members of the vascular endothelial growth factor (VEGF) family are commonly considered 
as key regulators of lymphatic vessel formation through the binding to their receptors 
(VEGFRs) expressed at the surface of LECs (Lemmon and Schlessinger, 2010). These 
growth factors induce the dimerization and autophosphorylation of their tyrosine kinase 
receptors, which then promote the activation of downstream signaling pathways involved in 
cellular responses (Mäkinen et al., 2001). The VEGF-C/VEGFR-3 axis is the best known 
signaling pathway in lymphangiogenesis. Its activation leads to the phosphorylation of serine 
kinases, such as phosphoinositide-3-kinase (PI3K)/Akt and mitogen-activated protein kinase 
(MAPK/ERK), which are crucial for LEC proliferation, tube formation, migration and 
survival (Zhang et al., 2010). Hence, blocking VEGFR-3/VEGF-C pathway is currently the 
best way to suppress lymphangiogenesis and the metastatic spread of tumor cells via 
lymphatic vessels (Norrmén et al., 2011; Quagliata et al., 2014). The inhibition of 
lymphangiogenesis holds promise for the treatment or prevention of tumor metastasis, but 
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unlike the antiangiogenesis strategy, the antilymphangiogenesis approach is yet to be tested 
clinically (Witte et al., 2011). However, new drugs with potential to inhibit 
lymphangiogenesis have been characterized in the recent years (Bock et al., 2013; Astin et 
al., 2014; Hos et al., 2014). 
Toluquinol, also denominated 2,5-toluenediol, is a 2-methylhydroquinone isolated from the 
culture broth of the marine fungus Penicillium sp. HL-85-ALS5-R004. In previous studies, 
we have reported the antiangiogenic activity of toluquinol through Akt signaling pathway 
suppression (García-Caballero et al., 2013). Toluquinol has been reported to inhibit the 
proliferation of blood endothelial and tumor cell lines, to suppress the capillary-like 
formation and migration of bovine aortic endothelial cells (BAEC), to decrease the matrix 
metalloproteinase (MMP)-2 secretion by BAEC and to induce tumor and blood endothelial 
apoptosis. Furthermore, toluquinol inhibited angiogenesis in the CAM assay, in the Matrigel 
plug assay and in the intersegmental vessel formation and caudal fin regeneration assays in 
zebrafish model (García-Caballero et al., 2013). Therefore, toluquinol seems to be a good 
example of the use of natural compounds, especially from marine organisms, as potential new 
sources of therapeutic compounds that could be used for the treatment of cancer or 
angiogenesis-related diseases (Bhatnagar and Kim, 2010; Senthilkumar et al., 2013; Khazir et 
al., 2014). 
In the present study, we evaluate the potential of toluquinol to inhibit lymphangiogenesis. To 
address this issue, a battery of in vitro, ex vivo and in vivo experimental models was used. We 
are providing for the first time evidence that toluquinol inhibits LEC proliferation, migration 
and sprouting of new lymphatic vessels. Additionally, toluquinol interferes with the in vivo 
lymphangiogenic process occurring during zebrafish development, with the lymphatic 
formation induced by VEGF-C in mice and with the corneal neovascularization. We 
demonstrate that toluquinol exerts its antilymphangiogenic properties by activating the 
apoptotic cascade initially, and specially by blocking VEGF-C/VEGFR-3 signaling pathway. 
Altogether, by showing that toluquinol inhibits several crucial steps of the lymphangiogenic 
process, our data open novel pharmacological perspectives for using this drug in diseases 
associated with abnormal lymphangiogenesis. 
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MATERIAL AND METHODS 
 
Group sizes 
For all the in vitro experiments the group size for each experimental condition was 5 
independent tests. 
For the ex vivo lymphatic ring assay the group size for each experimental condition was 10 
independent mouse rings collected from 5 different mice. 
Concerning the in vivo models the group sizes for each experimental condition were: 
    - Thoracic duct formation in the zebrafish model: n=50 embryos/condition 
    - Mouse ear sponge assay: n=5 mice/condition (2 sponges per mouse with a total of 10 
sponges from 5 mice per condition). The 2 samples from each mouse were averaged and the 
averaged number was used as a single “n” for statistical analysis. 
    - Mouse corneal neovascularization model: n=15 mice/condition (2 corneas per mouse 
with a total of 30 corneas from 15 mice per condition. The 2 samples from each mouse were 
averaged and the averaged number was used as a single “n” for statistical analysis. 
 
Randomization 
For all the experimental procedures, control and treated samples or animals were subjected to 
the same ambient conditions (identical tanks or cages, same incubator, identical behaviour, 
room lighting, temperature, etc.) and identical experimental settings, in order to obtain 
differences related only to drug incubation.  
 
Blinding 
All the quantifications were blinded. Once the operators performed the experimental battery, 
they assigned the nomenclature based on the letters A, B, C... to the different conditions. 
Therefore, the analyst did not know the origin of the data during sample’s quantifications. 
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Normalization 
In our work, data normalization was employed in the cases described below: 
- Cell growth analysis assessed by the MTT dye reduction test. In this approach, increasing 
amounts of viable cells results in increased purple colouring, and the cellular proliferation is 
proportional to the absorbance measured at 550 nm. In control wells (absence of drug), where 
the absorbance values were the highest, normalization was applied and the cellular 
proliferation was considered 100%. Thus, from the absorbance obtained in the wells with 
different drug concentrations, the percentage of viable cells was determined. Finally, the 
IC50 values were calculated as those concentrations of drug yielding 50% cell survival. 
- Viability/Cytotoxicity Assay. At each time point, numerical data were normalized according 
to the values obtained in control wells (untreated cells), which were considered as 100% for 
cell viability and 0% for cell cytotoxicity.  
- Scratch migration assay. In order to investigate the migratory capability of LEC, the 
surfaces of wounded areas at time 0, without migrated cells, were considered to have 0% of 
recovered areas. After different times of incubation, the surfaces occupied by migrated cells 
were determined by image analysis and the percentages of recovered areas were calculated by 
normalizing them with their respective values at time 0. 
- Caspase-3/-7 Assay. In this approach, the luminescence measured in control wells (non-
treated cells) was the lowest. Data were normalized considering that the luminescence in 
control wells was 100. 
- Western blotting analyses. For all the protein phosphorylation tests, the phosphorylated-
protein/total protein ratio was calculated. The maximum phosphorylation levels were always 
obtained in control conditions after stimulation with FBS or VEGF-C, VEGF-C156S or 
VEGF-A, in the different proteins studied in this work. The value of 100% was assigned to 
these ratios and the phosphorylation levels in presence of compound were normalized to their 
respective values in stimulated control conditions.  
- Mouse corneal neovascularization and ear sponge approaches. The data depicted in the 
Supplementary Figure 5 show the percentage of area, length, branching and end-point density 
inhibition in toluquinol-treated corneas. For these quantifications, normalizations were 
applied considering that the growth in control corneas was 100%, and results were expressed 
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as percentage of inhibition. For similar quantifications in the ear sponge samples, the vascular 
density measured in sponges soaked with VEGF-C and in absence of toluquinol was 
considered as 100%, and the normalized percentages of vascular inhibition upon toluquinol 
treatment are displayed in the Supplementary Figure 5. 
 
Validity of animal species or model selection 
This work considered the research on animals to carry out an excellent drug characterization 
on lymphangiogenesis phenomenon. Zebrafishes and mice were used for the reasons 
displayed below:  
- Zebrafish: although human pathologies have mostly been modelled using higher mammal 
systems like mice, the lower vertebrate zebrafish has gained tremendous attention as a model 
system. The advantages of zebrafish over classical vertebrate models are multifactorial and 
include high genetic and organ system homology to humans, high fecundity, external 
fertilization, ease of genetic manipulation, and transparency through early adulthood that 
enables powerful imaging modalities. Additionally, there are available several stable lines of 
transgenic zebrafish. In this work, the transgenic Fli:eGFPy1, which presents the endothelial 
cells labelled with the green fluorescent protein (GFP), was used. This model is very useful 
because it allows the fast and easy evaluation of the effect of compounds on the blood and 
lymphatic vascular systems. We focused in the effect of toluquinol in the thoracic duct 
development, which is a lymphangiogenesis-dependent process.  
- Mouse: the use of mice in research has led to major advances in our ability to know and 
treat a number of serious human diseases. Some of the advantages of the research on mice are 
the similarities to the human genome, the availability of a unique battery of sophisticated 
molecular and genetic tools, and the animal's small size. All together facilitate large 
scale/high throughput studies and make it a cost-efficient model, providing functional 
information about several diseases and allowing the test of new drugs, among others. In this 
work, mice were used to perform the lymphatic ring, the ear sponge and the corneal 
neovascularization assays.  The lymphatic ring assay is an ex vivo test which bridges the gap 
between in vitro and in vivo systems and allows the evaluation of compounds on different 
lymphangiogenic steps, such as proliferation, migration and tubulogenesis. The ear sponge 
assay is a new model using sponges that can be embedded with different factors (stimulators 
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and/or inhibitors) and can be easily placed into mouse ears, where there are a big amount of 
lymphatic vessels. This approach was used to analyze the ability of toluquinol to inhibit 
VEGF-C-stimulated lymphangiogenesis. The corneal neovascularization induced by thermal 
cauterization is an in vivo model that permits us the study of new lymphatic and blood vessels 
formation in the avascular cornea. Thus, is also possible to evaluate the interference of drugs 
with this vascular network. The corneal test was applied to investigate the ability of 
toluquinol to suppress lymph/angiogenesis under inflammatory conditions. 
 
Ethical Statement   
The animal procedures considered in this project were performed in strict compliance with 
the European Communities Council Directive 2010/63/EU and the Belgium legislation for 
the animal experimentation. The Local Animal Ethics Committee at the University of Liège 
approved the ethical and legal aspect of our experimental protocol before the starting of the 
research (number of ethical approval: 13/1522). Researchers working with animals received a 
specific training to reach the Category C from the Federation of European Laboratory Animal 
Science Associations (FELASA) before animal manipulation. All studies involving animals 
are reported in accordance with the ARRIVE guidelines for reporting experiments involving 
animals or animal tissue (Kilkenny et al., 2010; McGrath et al., 2010) and the 
recommendations of the Basel Declaration Society (2011), who are seeking to 
internationalize good practice (McGrath, McLachlan, Zeller, 2015). 
The main funding supporting this research was the “Tumorlymphainhibit”-625862 FP7-
PEOPLE-2013-IEF Marie Curie Fellowship from the European Commission. 
 
Animals  
- Transgenic Fli1:eGFPy1 adult zebrafishes (Danio rerio), aged 12-14 months, were from the 
International Resource Centre (ZIRC, Eugene, Oregon) and were maintained in the GIGA-
Zebrafish Facility (University of Liège, Belgium). The average body weight for the adult 
animals (used to obtain embryos) was ∼3 g. Male and female Fli1:eGFPy1 embryos at 24 h 
post-fertilization (hpf) were incubated in presence of compound and they were photographed 
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at 5 days post-fertilization (dpf). The average body weight for the embryo at 5 dpf was ∼0.15 
g. 
- Female C57BL/6 mice aged 8 weeks and 3 months were purchased from Janvier (Saint 
Berthevin, France). The 8 week-old C57BL/6 mice, with an average body weight of 16.5 g, 
were used for the ear sponge and corneal neovascularization assays. The 3 month-old mice, 
with an average body weight of 25 g, were used to perform the ex vivo thoracic duct test. 
 
Experimental Procedures 
Ex vivo experiments 
Three-dimensional mouse lymphatic ring cultures 
Lymphatic ring cultures were performed as previously described (Bruyère et al., 2008). 
Briefly, 3 month-old female C57BL/6 mice were sacrificed by beheading after making 
animals unconscious in a saturated-isoflurane bell-jar, the mouse skin was sterilized with 
ethanol 70% denatured and the thoracic duct was dissected with microdissecting forceps and 
iridectomy scissors sterilized by dry heat. After fibroadipodise tissue removing, thoracic 
ducts were cut into 1 mm long pieces fragments and they were embedded in a collagen gel. 
All the mentioned steps were carried out in a horizontal laminar flow hood (Cleanair, VWR, 
Belgium) to ensure sterile conditions. Explants were cultured in MCDB131 medium 
supplemented with 2% Ultroser (Pall Life Sciences, Washington, USA), 1% L-glutamine, 25 
mM NaHCO3, 100 U∙mL-1 penicillin and 100 µg∙mL-1 streptomycin, and in presence of 
toluquinol or vehicle (0.01% DMSO). The cultures were kept at 37°C in 5% O2, 5% CO2 and 
90% N2 for 7 days. For whole mounted immunostainings, at the end of the incubation, 
lymphatic rings were harvested from the agar cylinder, washed for 1 h in PBS, fixed for 30 
min with 80 % methanol, and kept at 4°C in 70 % ethanol until used. Then, gels were washed 
three times with PBS and blocked in 1.5% BSA-3% Gloria milk for 1 h at room temperature. 
The gels were incubated overnight with the appropriate primary antibody, rabbit anti-LYVE-
1/Biotin (1/500; ReliaTech GmbH, Germany) or mouse anti-Thy1.1 (1/100; Chemicon, 
Billerica, MA). After washing with PBS, gels were incubated with streptavidin/Alexa 
Fluor488 (1/100; Invitrogen, ThermoFisher, Belgium) or an Alexa Fluor 555-coupled goat 
anti-mouse secondary antibody (1/40; Invitrogen, ThermoFisher, Belgium), for 2 h at room 
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temperature. After 3 washes with PBS, gels were mounted on a microscope slide with 
Vectashield-DAPI mounting medium (Vector Laboratories, Burlingame, CA) and visualized 
with fluorescence and confocal microscopes (FSX100 Olympus, Hamburg, Germany; 
Confocal Leica TCS SP5, Leica Microsystems, Wetzl, Germany).  
In order to verify the lack of toxicity of toluquinol concentrations used in the lymphatic 
explants, the LIVE/DEAD® Viability/Cytotoxicity Kit (Molecular Probes, Invitrogen, 
Carlsbad, California) was applied at the end of the assay, according to the manufacturer’s 
instructions. 
Computerized quantifications were performed on binary images and a grid of concentric rings 
was generated by successive increments at fixed intervals of thoracic duct boundary (Bruyère 
et al., 2008). The number of microvessel-grid intersections was counted and plotted versus 
the distance to the ring to determine microvessel distribution. For the quantifications, 10 
rings/group were used.  
In vivo experiments 
Thoracic duct formation in zebrafish  
Transgenic Fli1:eGFPy1 zebrafish embryos at 24 h post-fertilization (hpf) were manually 
dechorionated with sterile forceps in a horizontal laminar flow workstation (Airstream, Esco 
Technologies, USA). Then, they were incubated in zebrafish water with the indicated 
concentrations of the tested compound at 28.5°C for 4 days. DMSO (0.02%) was used as 
both carrier of drug and control vehicle. To visualize the zebrafish thoracic duct after drug 
treatment, embryos were anesthetized with tricaine methanesulfonate 0.02% during 5 min 
(Sigma-Aldrich, Diegem, Belgium), mounted in 3% methyl cellulose and observed under a 
fluorescence Eclipse 90i microscope (Nikon, Japan) with acquisition software NIS-Elements 
3.00 (Nikon). Embryos were sacrificed by incubation with tricaine methanesulfonate 0.02% 
during 10 min. Quantification of the defective thoracic duct formation at 5 days post-
fertilization (dpf) was expressed as percentages of embryos with severe (no vessel, 0), drastic 
(5-25 % of normal thoracic duct length), moderate (25-90 % of normal thoracic duct length) 
and no (100% of normal thoracic duct length) lymphatic defects, as previously described 
(Detry et al., 2012). A total of 50 embryos were evaluated in each experimental condition. 
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Mouse ear sponge assay 
Mouse ear sponge assay was carried out following the protocol recently described (Lenoir et 
al., 2014). Sterile gelatin sponges (Gelfoam, Pfizer, Puurs, Belgium) were cut in small pieces, 
incubated with serum-free DMEM containing or not recombinant VEGF-C (1 µg∙mL-1) and 
different concentrations of toluquinol or DMSO (0.04%), and then, embedded in interstitial 
type I collagen gel. After anesthetizing the mouse with intraperitoneal injection (i.p.) of 
ketamine hydrochloride (100 mg/kg body weight) and xylazine (10 mg/kg body weight), ear 
skin was sterilized with ethanol 70% denatured and small incisions were made on the upper 
side of the ear of 8 week-old female C57BL/6 mice. Sponges were implanted between the 
two skin layers and every two days, serum-free DMEM containing toluquinol (0.5, 2 or 4 
nmol) or DMSO (controls) were injected in the apex of the ear. This manipulation was 
performed in a horizontal laminar flow hood Cleanair. It is worth mentioning that a pilot 
study was first conducted by using different toluquinol concentrations (0.2, 0.5, 2, 4 and 6 
nmol), in order to establish the appropriate concentration range demonstrating a dose-
response inhibition. After 3 weeks mice were sacrificed by cervical dislocation followed by 
decapitation and ears were excised, embedded and frozen in tissue optimal cutting 
temperature (OCT) compound (VWR Chemicals, Fontenay-sous-Bois, France). For 
lymphatic vasculature detection, sections were immunostained with polyclonal goat anti-
mouse LYVE-1 (1/200; R&D, Oxon, UK) and Alexa Fluor 488-coupled rabbit anti-goat 
(1/200; Molecular Probes, Gent, Belgium) antibodies. For blood vessel detection, a primary 
monoclonal rat anti-mouse antibody against CD31 (1/200, BD Biosciences Pharmingen, San 
Jose, CA) and a secondary Alexa Fluor 546-coupled goat anti-rat antibody (1/200; Molecular 
Probles, Gent, Belgium) were used. Images were acquired with a NanoZoomer 2.OHT 
scanner (Hamamatsu, Mont-Saint-Guibert, Belgium) and, the vessel area density and the 
lymphatic normalized frequency was determined using image analysis toolbox of Matlab 
R2013a(8.1.0.604) software. Sections from the two ears of each mouse were used for the 
quantification, obtaining a unique averaged value, and a total of 5 mice were established per 
group.  
 
Mouse corneal neovascularization assay 
The mouse corneal assay was performed as previously described (Detry et al., 2013). Briefly, 
after anesthetization with ketamine hydrochloride (100 mg/kg body weight) and xylazine (10 
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mg/kg body weight) injected i.p., the local anesthetic (Unicaïne 0.4%; Thea Pharma, 
Wetteren, Belgium) was applied and the central cornea was thermally cauterized using an 
ophthalmic cautery (Optemp II V; Alcon Surgical, Fort Worth, TX). One day after 
cauterization, 300 µL of PBS or PBS containing toluquinol (75 nmol) was daily i.p. injected 
until Day 9, or Day 40 post-cauterization in case of vascular regression analyses. At mice 
sacrifice by cervical dislocation followed by decapitation, corneas were dissected with sterile 
microdissecting instruments, whole mounted, fixed in ethanol 70%, blocked in 3% BSA-3% 
Gloria milk and immunostained as detailed for ear sponge assay. Corneas were visualized by 
using a fluorescent microscope Olympus FSX100 or a LeicaTCS SP2 inverted confocal 
microscope. The whole cornea picture was reconstitute with the Microsoft Image Composite 
Editor software and the lymphatic and blood vasculatures were quantified with the toolbox of 
Matlab R2013a(8.1.0.604) software. Corneas from the same animal were quantified and 
averaged. A total of 15 mice per group were evaluated for the statistical analysis. 
 
Housing and husbandry 
Transgenic zebrafishes, as well as mice used for the animal procedures, were maintained in 
the GIGA-Cancer Zebrafish and GIGA-Cancer Mouse Facilities, respectively, where existed 
an enrich environment with adequate temperature, humidity, food, etc. For the adult 
zebrafishes housing, the rack and tank system was used. They were maintained in 3 L 
polycarbonate aquarium tanks (20 zebrafish/tank) with a recirculating water system with the 
optimal physical, chemical and biological water characteristics. They were kept on a 14/10-h 
Light/Dark cycle, at a temperature of 27-28°C, and ZM-Fish Food with artemia nauplii were 
supplied twice per day. The transgenic eggs were obtained by natural mating when males and 
females were transferred to a 1.5 L breeding tank, with a ratio of two male and two females. 
Embryos were incubated at 28.5°C.  
Mice were housed in polycarbonate cages of 18 cm x 35 cm (5 mice/cage; according to the 
Royal Decree of 29/05/2013 from the Belgian Animal Welfare Legislation) with floors 
covered with sawdust bedding. They were maintained under a 12/12-h Light/Dark cycle with 
controlled room temperature (∼26°C) and humidity (35-75%), and were allowed ad libitum 
access to a diet of standard laboratory show and water. Caging equipment was sterilized, food 
irradiated and water filtered before their administration. 
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Interpretation 
Experiments involving animals were conducted with rigor, with the implementation of the 
3Rs principles, as defined by the National Centre for the Replacement, Refinement and 
Reduction of Animals in Research (NC3R). Efforts were made to reduce the number of 
animals used and minimize animal suffering. Furthermore, animals were anesthetised when it 
was necessary to decrease the animal pain and they were killed through the way that ensured 
less impact on the animal welfare. 
 
Cells and drug 
Human adult dermal microvascular lymphatic endothelial cells (LEC) were purchased from 
Lonza (HMVEC-dLy.Ad; Braine-l′Alleud, Belgium) and cultured in complete endothelial 
growth microvascular (EGM2-MV) medium (Lonza, Walkersville, MD, USA) composed of 
EBM-2 and singleQuotes (Detry et al., 2013). Toluquinol, provided by Biomar Institute S.A 
(León, Spain), was dissolved in dimethylsulfoxide (DMSO) at a concentration of 80 mM and 
stored in aliquots at -20°C until use. DMSO was used in controls at the same proportion used 
in experimental conditions. 
 
In vitro experiments 
Cell growth and cell viability/cytotoxicity assays 
The MTT (Sigma-Aldrich, Diegem, Belgium) dye reduction assay was applied to LECs 
(3x10
3 
cells/well) in 96-well microplates (García-Caballero et al., 2013). For cell growth 
determinations, the IC50 values were calculated as concentrations of toluquinol yielding 50% 
cell survival, taking the values obtained for control as 100%. For viability/cytotoxicity tests, 
LECs were plated in 96-well plates (15000 cells/well) and treated with the highest toluquinol 
concentration (5 μM) applied in in vitro experiments, for different incubation times. Then, 
two differential fluorogenic protease biomarkers, GF-AFC and bis-AAF-R110, provided in 
the ApoTox-GloTM Triplex Assay kit (Promega Corporation, Madison, WI, USA) were 
simultaneously added in a single nonlytic reagent. The fluorescence was recorded with a 
Victor X3 Multilabel Plate Reader (PerkinElmer, Waltham, USA). All determinations were 
carried out in quadruplicate and five independent experiments were performed.  
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LEC migration assay 
For the scratch migration assay (Liang et al., 2007), confluent monolayers were wounded 
with pipette tips and supplied with EGM-2 medium containing 2% FBS, mitomycin C (0.1 
µg∙ml-1; Sigma-Aldrich, Diegem, Belgium) and different toluquinol concentrations. Wounded 
areas were photographed at different times of incubation using a phase-contrast microscope 
(Axiovert 25, Zeiss Microscopy, Zaventem, Belgium). The percentage of recovered area at 24 
and 48 h was determined by image analysis, normalizing them with their respective values at 
time 0. The NIH Image 1.6 software was used for quantification and five independent 
experiments were evaluated. 
 
Tubulogenesis assay 
LECs (5x10
5
/well) were embedded in a 1:1 mix of collagen R solution (Serva, Heidelberg, 
Germany) and derived Hanks' Balanced Salt Solution (HBSS; Gibco, New York, USA) 
containing or not the drug, and cultured in 2% FBS supplemented EGM-2 medium with or 
without toluquinol. Tube formation was monitored in the next 24 h. Pictures were 
photographed with an inverted and phase-contrast microscope. Results were expressed as the 
area density of tubes, defined as the area occupied by tubes divided by the total area of the 
studied field. Five independent assays were carried out and the Matlab R2013a4(8.1.0.604) 
image analysis toolbox software was used for the tubes quantification. 
 
Spheroid assay 
In order to generate multicellular microspheres, 1.5x10
3
 LECs/well were pre-cultured in 
EBM-2 medium containing 1% FBS and 0.24% high viscosity methyl cellulose (Sigma-
Aldrich, Diegem, Belgium) for 24 h. Spheroids were then embedded in collagen gels 
containing or not toluquinol and cultured in 2% FBS supplemented EGM-2 medium with or 
without the drug. After 24 h, photos of spheroids were taken using a phase-contrast 
microscope and a computer-assisted quantification was used as described in Blacher et al., 
2014. In some assays, cells were stained during 30 min, with green or orange CellTracker 
Dye (Life Technologies, Thermo Fisher Scientific, Belgium). Green and orange stained cells 
were mixed in a 1:1 proportion to generate spheroids as above described. Cell sprouting was 
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analyzed with an epifluorescence microscope (Nikon Eclipse Ti) after 12 h of incubation. For 
statistical analysis, at least 8 spheroids/group were analyzed in each individual experiment 
and five independent experiments were performed. 
 
Apoptosis and cell cycle experiments 
After treatment with the indicated toluquinol concentrations for 14 h, apoptosis assays were 
carried out by staining of nuclei with Hoechst, cell cycle analysis by flow cytometry and 
through the evaluation of caspase-3/-7 activity. To analyze nuclear morphologic changes, 
cells were treated, washed with PBS, fixed with formalin solution (Sigma-Aldrich, Madrid, 
Spain) and stained with Hoechst 33258 (1 µg∙mL-1; Sigma-Aldrich, Madrid, Spain) in PBS. 
Subsequently, cells were mounted on slides using DAKO Cytomation Fluorescent Mounting 
Medium (DAKO, Denmark) and observed under a fluorescence microscope (Leica, TCS-NT, 
Heidelberg, Germany). For cell cycle analysis, LECs were washed with PBS, fixed with ice-
cold 70% ethanol during 1 h on ice, centrifuged and suspended in propidium iodide staining 
solution (40 μg∙mL-1 propidium iodide and 0.1 mg∙mL-1 RNase-A in PBS; Sigma-Aldrich, 
Madrid, Spain). After 1 h of incubation with shaking and protected from light, percentages of 
subG1, G1 and S/G2/M populations were determined using a MoFlo Dakocytomation 
cytometer (Dako, Denmark) and the Summit 4.3 software. For the determination of caspase-
3/-7 activity, LECs were plated in 96-well plates (15000 cells/well) and treated with or 
without different toluquinol concentrations for different times of incubation. Then, Caspase-
Glo® 3/7 reagent, provided in the ApoTox-GloTM Triplex Assay Kit, was added to the wells 
according to the manufacturer’s instructions, and the luminescence was recorded at 30 min 
with a PerkinElmer's VICTORX3 Multilabel Plate Reader. Five independent experiments 
were analyzed in the three different approaches.  
 
Western-blotting analyses 
In order to detect VEGFR-3 and VEGFR-2 phosphorylated versus total proteins, and 
downstream targets, such as p-Akt, Akt, p-ERK and ERK, subconfluent LEC cultures were 
incubated in serum-free EBM-2 medium for 24 h. Then, toluquinol or vehicle (0.02% 
DMSO) was added in the cultures for 2 h and challenged for 30 min with either recombinant 
human VEGF-C (400 ng∙mL-1; R&D Systems, Oxon Abingdon, UK), recombinant human 
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VEGF-C156S (500 ng∙mL-1; R&D Systems) or recombinant human VEGF-A (100 ng∙mL-1; 
R&D Systems). After stimulation, cells were rinsed with ice-cold PBS and scrapped with 
RIPA (Radio-Immunoprecipitation Assay) buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholate, NP40 1% and SDS 0.1%) containing phosphatase 
and protease inhibitors (Roche, Mannheim, Germany). Cell extracts were centrifuged at 
16000 rpm for 15 min at 4°C, evaluated for protein concentration and stored at -80°C until 
the moment of analysis. Afterwards, samples were denatured for 5 min at 95°C and subjected 
to 10% SDS-PAGE electrophoresis. After electrotransfer on PVDF membranes, 
phosphorylated and total proteins were detected by 4°C overnight incubation with the 
indicated antibodies followed by 1 h incubation at room temperature with Horseradish 
Peroxidase-coupled secondary antibody (Cell Signaling, San Diego, CA). The 
immunoreactive bands were detected using a chemiluminescence system (ECL Western 
Blotting Substrate, Pierce, Rockford, USA) with an imaging system (LAS4000 imager, 
Fujifilm, Tokyo, Japan). The following antibodies were used: rabbit monoclonal p-VEGFR-3 
(1/1000; Cell Application, San Diego, CA), rabbit monoclonal p-Akt, Akt, p-ERK1/2, 
ERK1/2, p-VEGFR-2, VEGFR-2 (1/1000; Cell Signaling, San Diego, CA), and mouse 
monoclonal VEGFR-3 (1/1000; Millipore, Carrigtwohill, Ireland). Membranes were 
incubated with an anti-GAPDH primary antibody (1/2000; Millipore) to ensure equal loading. 
At least, five western-blots were carried out and the phosphorylated protein/total protein 
ratios were calculated from five independent tests. 
 
Statistical analysis 
Results are given as mean ± SEM. Statistical analysis was carried out with the GraphPad 
Prism 5.0 programme to compare the differences between control conditions in absence of 
compound and the different toluquinol concentrations. Mann-Whitney-Wilcoxon tests were 
used to decide if the differences among means were statistically significant and P<0.05 
constituted the threshold for the significance level. Significant differences are indicated in the 
figures as *P<0.05. Data and statistical analysis comply with the recommendations on 
experimental design and analysis in pharmacology (Curtis et al., 2015). 
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RESULTS 
Toluquinol inhibits LEC growth and decreases LEC viability  
We first examined the impact of toluquinol (Figure 1A) on LEC proliferation using the MTT 
assay. Toluquinol inhibited the growth of actively growing LECs in a dose-dependent manner 
with an IC50 value of 6.2 ± 2 µM (Figure 1B). Moreover, aiming at evaluating the cell 
viability/cytotoxicity in presence of toluquinol 5 M (highest toluquinol concentration used 
in vitro) the ApoTox-Glo
TM 
Triplex Assay kit was used. Toluquinol decreased the cell 
viability by 34% upon 14 h of treatment, but low cytotoxicity (<13%) was found after 48 and 
72 h of drug exposition (Figure 1C).  
 
Toluquinol inhibits LEC migration 
A scratch assay was carried out to examine the impact of toluquinol on LEC migration 
(Figure 2). To determine whether a putative inhibitory effect could be related to an effect on 
cell proliferation, mitomycin C was always added in the culture medium after wounding, and 
pictures were taken at time 0 and after 24 and 48 h (Figure 2A). In control conditions, 50% of 
the scratch area was recovered by migrating LECs after 24 h. Upon toluquinol 1, 2.5 and 5 
µM treatment, 45.4%, 9.1% and 5.5% of the wounded areas were recovered after 24 h, 
respectively (Figure 2B). This drastic migratory inhibition was also observed after 48 h of 
scratching with toluquinol at 2.5 and 5 µM (Figure 2B). Thus, toluquinol exerted a dose-
dependent inhibitory effect on LEC migration after 24 and 48 h of scratching. Additional 
experiments revealed that the effect of toluquinol is reversible, since pretreated LECs with 5 
µM toluquinol for 24 h and incubated in EGM-2 medium containing 2% FBS (in absence of 
drug), were able to migrate and close the wounded areas in a similar way than control cells 
after 48 h (Supporting Information Figure S1). 
Toluquinol suppresses tube formation and LEC sprouting in a collagen matrix 
In a first 3D approach, LECs were seeded between 2 collagen gels in order to generate tube-
like structures after 24 h of culture. In the presence of toluquinol, the tubular network was 
disorganized (Figure 3A). Toluquinol inhibited lymphatic tubulogenesis in a dose-dependent 
manner with optimal effect reached at 5 µM (Figure 3B). As a second 3D model, LEC 
spheroids were embedded in a collagen matrix to mimic the sprouting, migration and tube 
formation of lymphatics. Within 24 h, untreated spheroids sprouted from the initial 
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microsphere core (Figure 4A). In sharp contrast, LECs from 5 µM toluquinol-treated 
spheroids failed to spread out (Figure 4A). A dose-dependent inhibition of cell sprouting was 
again observed as assessed by the determination of various quantitative parameters (Blacher 
et al., 2014). Firstly, the convex envelope area, corresponding to the area occupied by the 
spheroid core and the migrated cells, was determined, and its value after 5 µM toluquinol 
treatment was significantly lower (0.09 mm
2
) than in control condition (0.39 mm
2
) (Figure 
4B). Secondly, the estimation of migrated cells per area revealed also a maximal inhibition at 
5 µM of toluquinol. Finally, the quantification of cell distribution around the spheroid core 
further supported the drastic inhibition of LEC migration when toluquinol was used at the 
highest concentration (Figure 4B). The maximal distance of LEC migration (Lmax) was 0.26 
mm at 5 µM and 0.4 mm at the other conditions. In order to check the reversibility of the 
inhibitory effect elicited by toluquinol, some mixed spheroids were generated with green and 
orange stained cells (1:1 proportion). After 12 h, in non-treated mixed spheroids, green and 
orange stained LECs migrated in a similar extend (“1” in Figure 4C). On the opposite, when 
green and orange cells were mixed and embedded in a collagen matrix containing 5 µM 
toluquinol, no sprouting was detected (“2” in Figure 4C). However, when spheroids were 
generated with green LEC pretreated with toluquinol (5 µM), both LECs stained in orange 
and in green sprouted from the spheroid (“3” in Figure 4C). These findings demonstrate the 
reversibility of these effects elicited by this compound.  
 
Toluquinol induces LEC apoptosis  
To further determine whether toluquinol induces LEC apoptosis, chromatin morphology was 
analyzed in treated and untreated cells stained with Hoechst 33258 (Figure 5A). Toluquinol 
promoted chromatin condensation at 2.5 and 5 µM upon 14 h of treatment in 18% and 48% 
of cells, respectively (Figure 5B). Less than 4% of apoptotic nuclei was observed with 
toluquinol used at 1 µM. A dose-dependent apoptosis induction was thus observed with the 
used toluquinol doses. Cell cycle analyses by flow cytometry were next conducted in control 
and toluquinol-treated LECs after propidium iodide staining. The apoptotic subG1 cell 
subpopulation was significantly increased upon toluquinol treatment for 14 h (Figure 5C), 
leading to a 3-fold increase of apoptotic LEC percentage at 5 µM of toluquinol compared 
with control condition (Figure 5D). In addition, the “effector” caspase-3/-7 activity, which 
plays a key role in the induction of apoptosis, was determined in LEC cultures. LEC caspases 
were activated upon treatment with 2.5 and 5 µM toluquinol for 14 h (Figure 5E). However, 
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this initial 1.5-fold enhancement of caspase activation observed upon 5 µM toluquinol 
treatment was not anymore detected after 48 and 72 h of incubation (Figure 5F). 
 
Toluquinol suppresses VEGFR-3 phosphorylation, and MAPK/ERK1/2 and PI3K/Akt 
downstream activations in LECs 
A mechanistic exploration of the inhibitory effect of toluquinol on LECs was next conducted 
by focusing on VEGFR-2 and VEGFR-3, the two main receptors involved in 
lymphangiogenesis, and their downstream signaling pathways PI3K/Akt and MAPK/ERK1/2 
(Olsson et al., 2006; Bahram and Claesson-Welsh 2010; Deng et al., 2015). We used VEGF-C, 
VEGF-C156S and VEGF-A in order to examine the effect of toluquinol on VEGFR3- versus 
VEGFR2-induced LEC activation. As expected, stimulation with VEGF-C resulted in 
VEGFR-3 activation, as well as Akt and ERK1/2 phosphorylations, as assessed by Western 
blotting (Figure 6A). A pretreatment with toluquinol 5 M decreased VEGFR-3, Akt and 
ERK1/2 phosphorylation levels. Similarly, VEGFR-3, Akt and ERK activations were 
obtained after stimulation with VEGF-C156S, a mutant VEGF-C form, which binds VEGFR-
3, but not VEGFR-2. Interestingly, under this experimental condition, a stronger impact of 
toluquinol on p-VEGFR-3, p-Akt and p-ERK inhibition was seen at 2.5 and 5 µM (Figure 
6B). However, when VEGF-A was used as the more potent VEGFR-2 stimulator, toluquinol 
failed to interfere with VEGFR-2 activation and no reduction of VEGFR-2 phosphorylation 
levels was observed in toluquinol-treated LECs. It is worth noting that p-Akt and p-ERK 
levels were diminished in toluquinol-treated and VEGF-A-stimulated LECs, suggesting a 
modulation of downstream effectors (Figure 6C). Quantifications expressed as 
phosphorylated protein/total protein ratios are displayed in the Supporting Information Figure 
S2 and complete Western blot membranes are presented in the Supporting Information Figure 
S3. 
 
Toluquinol decreases the ex vivo outgrowing from mouse thoracic explants 
To validate the antilymphangiogenic potential of toluquinol found with in vitro assays, next 
we tested it in an ex vivo assay. Explants from mouse thoracic ducts were cultured under 
hypoxic conditions to analyze the ex vivo lymphatic outgrowth. A remarkable outgrowth of 
LECs from control rings (with DMSO) was observed after 7 days of incubation (Figure 7A). 
In sharp contrast, explants exposed to 2.5 and 5 µM toluquinol exhibited a significant 
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outgrowth reduction and only a very slight LEC migration was observed in the presence of 
toluquinol at 7.5 µM (Figure 7A). It is worth noting that the influence of toluquinol in the 
lymphatic ring assay was examined in the presence of 2% Ultroser G to ensure an optimal 
lymphangiogenic reaction in all the explants. For computerized quantification, a grid of 
concentric circles was used and the number of microvessel intersections with this grid was 
estimated at different distances to the lymphatic ring. A dose-dependent reduction of cell 
migration was observed with toluquinol (Figure 7B). The number of microvessel 
intersections at 0.25 mm from the lymphatic ring reached the value of 280 for control rings 
and 170, 98 and 43 for 2.5, 5 and 7.5 µM toluquinol, respectively (Figure 7B). The absence 
of toluquinol toxicity was checked at the end of this assay with the highest concentration used 
(Supporting Information Figure S4A). Additionally, the lymphatic endothelial cell origin of 
sprouting cells was assessed by immunostainings on whole mounted explants, revealing the 
LYVE-1 positivity of outgrowing cells (Supporting Information Figure S4B). To verify the 
absence of outgrowing fibroblasts, an anti-Thy1.1 antibody was used, showing the absence of 
migrating fibroblasts (Supporting Information Figure S4C-E). Only one cell appeared 
positive (stained in red), but it was located in the ring (Supporting Information Figure S4C). 
 
Toluquinol inhibits in vivo zebrafish lymphangiogenesis  
In zebrafish, the thoracic duct generated by lymphangiogenesis is located between the dorsal 
aorta and the posterior cardinal vein (Figure 8A). Its development starts around 30 to 50 hpf 
being completed at 3 to 6 dpa. Embryos from a transgenic fli1:EGFPy1 zebrafish line (that 
drives the GFP expression in the endothelium) were treated with different amounts of 
toluquinol added in zebrafish water. In this approach, the direct addition of the drug to the 
water justified the use of a different range of concentrations from that used in vitro and in 
vivo, but similar to doses applied previously (García-Caballero et al., 2013) for the 
antiangiogenic effect of toluquinol in zebrafish. Thus, after 4 days of incubation with 
compound, we analyzed fish morphology with a special focus on the thoracic duct. Embryos 
subjected to toluquinol treatment displayed a normal morphology with normal body size and 
trunk circulation. No obvious tissue malformation, retarded development or other toxic signs 
were detected. Toluquinol concentration ≥ 15 µM induced dramatic thoracic duct defects in 
zebrafish (Figure 8B). The percentages of embryos with severe (no vessel, lymphatic 
abrogation), drastic (5-25 % of normal thoracic duct length), moderate (25-90 % of normal 
thoracic duct length) or no (100% of normal thoracic duct length) lymphatic defects were 
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determined (Figure 8C). At 5 dpa, the thoracic duct failed to form in 20% of 20 µM 
toluquinol-treated zebrafishes, exceeded its normal length by 5-25% in 22% of embryos and 
only 34% of embryos had normal length thoracic duct. In the presence of toluquinol at doses 
lower than 15 µM, the antilymphangiogenic effect was less apparent (Figure 8C). Table 1 
summarizes data related to the percentage and the number of embryos with the mentioned 
phenotypes.  
 
Toluquinol affects in vivo mouse VEGF-C-induced lymphangiogenesis  
Next, we extended our analyses by using the mouse ear sponge assay, allowing the 
concomitant study of lymphangiogenesis and angiogenesis. In this murine model, fragments 
of gelatin sponges were embedded in collagen containing either DMEM (negative control) or 
VEGF-C (positive control), or a mix of VEGF-C and different amounts of toluquinol. These 
sponges were implanted into mice ears. Every two days DMEM with the vehicle or DMEM 
supplemented with toluquinol were injected in the apex of the ear for 21 days. The blood and 
lymphatic networks were analyzed by CD31 and LYVE-1 immunostainings, respectively. A 
huge amount of blood vessels and only few lymphatic vessels were observed in sponges 
soaked with DMEM (Figure 9A). As expected, sponges soaked with VEGF-C (1 µg∙mL-1) 
exhibited a 4-fold increase in the infiltrating lymphatic vessels, with slight effect on the blood 
vasculature (Figure 9A,B). The in vivo administration of toluquinol to mice induced a clear 
dose-dependent reduction in the area occupied by lymphatic vessels (Figure 9A). Indeed, 2-
fold and 4-fold decreases in the lymphatic area were detected after administration of 
toluquinol at 2 and 4 nmol, respectively (Figure 9B). Upon drug administration, most 
lymphatic vessels remained located close to the sponge border, and the Lmax in sponges 
embedded with 4 nmol of drug did not exceed 1.5 mm from the sponge edge (Figure 9B). In 
contrast, in VEGF-C embedded sponges without drug, Lmax was superior of 2 mm (Figure 
9B). Notably, no significant angioinhibitory effect of toluquinol was seen at the tested doses, 
as assessed by CD31 stainings (Figure 9A,B), and although toluquinol exerted up to 80% of 
lymphangiogenesis inhibition, the angiogenic response was only reduced by about 30% 
(Supporting Information Figure S5A). 
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Toluquinol reduces the corneal neovascularization in mice  
Corneal neovascularization was induced in mice daily injected i.p. with 300 µL of 3 different 
toluquinol doses. Based on this first test and according to the 3Rs principles, we used 0.25 
mM toluquinol (75 nmol of toluquinol) as the most optimal dose, in order to repeat the study 
by increasing the group size.  
At Day 9 post-injury, in cauterized corneas (Figure 10A-D), lymphatic (stained in green) and 
blood (stained in red) vasculatures grew out of the limbus to the central part of the cornea. A 
clear reduction in both lymphatic and blood vascular networks was detected in corneas 
dissected from treated mice (Figure 10A-D). The computer-assisted quantification revealed 
that toluquinol reduced the area, length, branching and end-point densities of both, lymphatic 
(Figure 10G) and blood (Figure 10H) vasculatures. Lmax was also significantly reduced 
(Lmax for lymphatic vessels = 1.99 in controls versus 1.5 in toluquinol-administered mice; 
Lmax for blood vessels = 1.65 in controls versus 1.36 in toluquinol-administered mice) 
(Figure 10I). Notably, toluquinol was more potent on lymphangiogenesis than on 
angiogenesis for all the parameters quantified. Indeed, as shown in Supporting Information 
S5B, higher percentage of inhibition (except for the end point density) was found for corneal 
lymphatic vasculature as compared to blood one. 
We next visualized the corneas under a confocal microscope in order to analyze the migrating 
cells at the tip of the lymphatic buds, characterized by numerous cytoplasmic extensions or 
filopodias. Interestingly, the number and length of filopodias was higher in control corneas 
(7 filopodia-like extensions and with a length of 8.2 m) than in toluquinol-treated corneas 
(3 filopodia-like extensions and with a length of  4.7 m) (Figure 10E,F,J).  
Since toluquinol induced apoptosis in vitro upon 14 h of treatment, we wondered whether this 
drug was able to provoke apoptosis and vessel regression in vivo. We thus determined blood 
and lymphatic vessel densities in mice treated or not with toluquinol (75 nmol) for 40 days 
post-cauterization, and a clear reduction in both neovasculatures was detected in treated mice 
(Supporting Information S6A). As expected, the lymphatic and blood vascular densities were 
lower at Day 40 than at Day 9, in control and treated mice, and the regression of the blood 
vasculature was more pronounced than that of the lymphatic network (Supporting 
Information S6B). Nevertheless, no significant difference in vessel regression was seen 
  
This article is protected by copyright. All rights reserved. 
between control and treated mice after 40 days post-cauterization (Supporting Information 
S6B).       
 
DISCUSSION 
Lymphatic vessels are critical for health and are involved in fluid drainage, lipid transport 
and inflammation. Since excessive lymphangiogenesis favors cancer cell metastasis, 
inflammation and graft (renal, corneal) rejection, lymphangiogenesis inhibition holds promise 
in different pathological contexts (Alitalo 2011). Here, we provide in vitro, ex vivo and in 
vivo evidence that toluquinol (isolated from the marine fungus Penicillium) is a potent 
inhibitor of lymphangiogenesis. Mechanistically, this antilymphangiogenic effect relies on 
the inhibition of VEGFR-3 phosphorylation and downstream signalings. We have previously 
reported that toluquinol exerts antiangiogenic inhibitory activities (García-Caballero et al., 
2013). Indeed, we reported that toluquinol inhibited in vitro tumor proliferation, endothelial 
capillary tube-like formation and migration, and in vivo angiogenesis by targeting Akt 
signaling pathway. We are now assigning new antilymphangiogenic activities to toluquinol, 
which are supported by the use of a panel of in vitro, ex vivo and in vivo models 
recapitulating the different steps of the complex lymphangiogenic process. 
The present study sheds light on the antilymphangiogenic potential of toluquinol and its 
molecular mechanisms of action to abolish this process. Toluquinol significantly decreased 
LEC proliferation, migration and lymphatic tube formation in a dose-dependent manner with 
concentrations ranging from 1 to 5 µM with an IC50 value of 6.2 µM. It is worth mentioning 
that the effective dose of toluquinol observed in the described in vitro assays is in agreement 
with the effective dose displayed by toluquinol as an angiogenic inhibitor (García-Caballero 
et al., 2013). Importantly, an apoptotic effect of toluquinol was clearly detected upon 14 
hours of treatment, since LECs exhibited some typical features of apoptosis, including 
increased chromatin condensation, augmentation in the percentage of cells with subdiploid 
DNA content (subG1 phase) and an enhancement of the effector caspase-3/-7 activity. 
However, 3 days after toluquinol addition, the caspase activity slowed down to basal levels. 
Accordingly, a decrease in LEC viability was detected at early time point, but not after 72 h 
of treatment. Therefore, the apoptotic effect of toluquinol can contribute to the detected 
growth inhibitory effect and the antilymphangiogenic activity exhibited by this compound on 
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LECs, but only in its initial antilymphangiogenic action. This observation is also in 
agreement with the drug reversibility demonstrated in migration assays. 
The potent impact of toluquinol on LEC migration was demonstrated in 2D and 3D models of 
migration, namely the wound healing, the tubulogenesis and the spheroid assays. The 
spreading of lymphatic cells from a pre-existing vessel was also assessed by the thoracic duct 
ring assay, revealing similar inhibitory effects, with a partially inhibition at 5 µM and a 
complete lymphatic outgrowth suppression at 7.5 µM. In a developmental model with 
zebrafish embryos, toluquinol impaired thoracic duct formation at 15 µM, leading to 
lymphatic abnormalities in 66% embryos treated with 20 µM toluquinol. The examination of 
the embryos revealed the inhibition of the lymphangiogenic process without evidence of 
toxicity, developmental delay and others unhealthy signs. However, due to the capacity of 
toluquinol to interfere with the angiogenic process (García-Caballero et al., 2013) we cannot 
exclude an indirect effect on lymphangiogenesis in this developmental model. The 
antilymphangiogenic action of toluquinol is supported in vivo by the strong inhibitory effects 
observed in gelatin sponges soaked with VEGF-C and by the mouse corneal assay.  
Mechanistically, we provide evidence that toluquinol interferes with VEGF-C-induced 
VEGFR-3 phosphorylation, but not VEGF-A-mediated VEGFR-2 phosphorylation. 
Interestingly, toluquinol appears more potent to block VEGFR-3 homodimers than VEGFR-
3/VEGFR-2 heterodimers, since is more efficient on cells stimulated with the mutated form 
of VEGF-C (VEGF-C156S), which only binds the homodimer, than on cells treated with the 
wild type VEGF-C form, which is able to stimulate both the homodimer and the heterodimer 
(Dixelius et al., 2003; Lohela et al., 2003; Deng et al., 2015). After dimerization and 
autophosphorylation, VEGFR-3 serves as a docking site for downstream signaling molecules 
involving mainly Akt and ERK1/2 pathways (Zhang et al., 2010). Importantly, we also found 
a repression of downstream signaling mediators (Akt and ERK) in stimulated LECs, 
suggesting that components of these signaling cascades could also be major targets in the 
molecular mechanism of toluquinol. 
One important finding of our work is that toluquinol is a more potent inhibitor of 
lymphangiogenesis than angiogenesis. Indeed, no significant effect on angiogenesis was 
detected in the sponge assay at the tested concentrations (up to 4 nmol), although a reduction 
in the lymphatic vasculature was evident. We previously reported that toluquinol displayed 
antiangiogenic activity in the in vivo Matrigel plug assay, in which we used 30 nmol, a 7.5-
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fold higher concentration than that used herein in the gelatin sponges (García-Caballero et al., 
2013). In addition, it is worth mentioning that in this assay, FGF-2 was used instead of 
VEGF-C for angiogenesis stimulation. In the corneal assay, toluquinol was again more potent 
on the neoformed lymphatic vasculature than on the blood one. It is also worth underlying the 
capacity of toluquinol to decrease the number of structure-like filopodias at the end of the 
corneal lymphatic bud, suggesting an impact on tip cell specification. Altogether, the more 
potent antilymphangiogenic effect of toluquinol fits with its ability to primarily inhibit 
VEGFR-3 phosphorylation without affecting VEGFR-2 activation. 
Through its property to block VEGF-C/VEGFR-3 axis, toluquinol appears as a good 
candidate for diverse therapeutic applications. Several antitumor drugs displaying 
lymphangiogenic inhibitory properties and regulating the VEGFR-3 signaling pathway 
include, among others, deguelin (Hu et al., 2010), endostar (Dong et al., 2011), liposomal 
honokiol (Wen et al., 2009), Ki23057 (Yashiro et al., 2009), etodolac (Iwata et al., 2007), 
MMI270 (Nakamura et al., 2004), CSDA (Matsumoto et al., 2010) and norcantharidin (Liu et 
al., 2012). Blocking the VEGFR-3 cascade has been reported to impair metastatic 
dissemination and tumor growth in lymph nodes (Sleeman and Thiele, 2009). Thus, has been 
experimentally demonstrated that lymph node-specific antibody-mediated inhibition of 
VEGFR-3 activation in response to VEGF-C draining to the nodes from metastatic breast 
tumors inhibits the outgrowth in these nodes (Quagliata et al., 2013). Besides cancer and 
metastasis, ocular diseases can also be associated with abnormal lymphangiogenesis. 
Although the cornea is normally avascular, some infectious, traumatic, degenerative and 
inflammatory diseases can induce corneal neovascularization, leading to diminished visual 
acuity (Epstein et al., 1987; Bock et al., 2013). Indeed, corneal neovascularization is the 
second cause of blindness worldwide and it is associated with the risk of cornea graft 
rejection (Bachmann B et al., 2010). Therefore, pharmacological inhibition of corneal 
lymph/angiogenesis represents an attractive therapeutic option and drugs like bevacizumab 
are now available in the clinic to treat ocular pathologies by targeting lymph/angiogenesis 
(Amadio et al., 2016). Lymphangiogenesis is also associated with skin inflammatory 
disorders like psoriasis (Varricchi et al., 2015), and atherosclerosis (Aspelund et al., 2016). In 
this context, our results suggest a promising role for toluquinol in multiple biomedical fields, 
such as inflammatory diseases and malignancies associated with an excessive 
lymphangiogenesis. 
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CONCLUSIONS 
Data shown here bring new insights into antilymphangiogenic properties of toluquinol, and 
we demonstrate for the first time that toluquinol represses lymphangiogenesis by 
downregulation of VEGF-C/VEGFR-3 cascade. The present work emphasizes the potential 
value of toluquinol in the pharmacological treatment of pathologies with an excessive 
lymphangiogenesis, since it is able to block LEC proliferation, migration and tubulogenesis, 
and to induce LEC apoptosis. In line with our previous study, these findings extend the 
applicability of toluquinol from angiogenesis to lymphangiogenesis. Hence, targeting 
VEGFR-3 seems a realistic therapeutic strategy for inhibiting tumor-induced 
lymphangiogenesis and lymph node metastasis, making toluquinol a promising candidate for 
further preclinical testing. Furthermore, due to its ability to suppress corneal 
neovascularization, therapeutic approaches could be pursued in the prevention and treatment 
of vascular pathologies of the cornea and in the increase of cornea graft survival. 
 
REFERENCES 
Abdelfattah NS, Amgad M, Zayed AA, Salem H, Elkhanany AE, Hussein H et al. (2015). 
Clinical correlates of common corneal neovascular diseases: a literature review. Int J 
Ophthalmol 8: 182-93. 
Achen MG, Stacker SA (2008). Molecular control of lymphatic metastasis. Ann N Y Acad 
Sci 1131: 225-234. 
 
Alitalo A, Detmar M (2012). Interaction of tumor cells and lymphatic vessels in cancer 
progression. Oncogene 31: 4499-4508. 
 
Alitalo K (2011). The lymphatic vasculature in disease. Nat Med 17: 1371-1380.  
 
Amadio M, Govoni S, Pascale A (2016). Targeting VEGF in eye neovascularization: What's 
new?: A comprehensive review on current therapies and oligonucleotide-based interventions 
under development. Pharmacol Res 103: 253-69. 
Astin JW, Jamieson SM, Eng TC, Flores MV, Misa JP, Chien A et al. (2014). An in vivo 
antilymphatic screen in zebrafish identifies novel inhibitors of mammalian 
lymphangiogenesis and lymphatic-mediated metastasis. Mol Cancer Ther 13: 2450-2462. 
 
Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K (2016). Lymphatic System in 
Cardiovascular Medicine. Circ Res 118(3): 515-30. 
 
  
This article is protected by copyright. All rights reserved. 
Bachmann B, Taylor RS, Cursiefen C (2010). Corneal neovascularization as a risk factor for 
graft failure and rejection after keratoplasty: an evidence-based meta-analysis. 
Ophthalmology 117: 1300-1305. 
 
Bahram F, Claesson-Welsh L (2010). VEGF-mediated signal transduction in lymphatic 
endothelial cells. Pathophysiology 17: 253-261. 
 
Bhatnagar I, Kim SK (2010). Immense essence of excellence: marine microbial bioactive 
compounds. Mar Drugs 8: 2673-2701.  
 
Blacher S, Erpicum C, Lenoir B, Paupert J, Moraes G, Ormenese S et al. (2014). Cell 
invasion in the spheroid sprouting assay: a spatial organisation analysis adaptable to cell 
behaviour. PLoS One 9: e97019.  
 
Bock F, Maruyama K, Regenfuss B, Hos D, Steven P, Heindl LM et al. (2013). Novel 
anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog 
Retin Eye Res 34: 89-124. 
 
Bruyère F, Melen-Lamalle L, Blacher S, Roland G, Thiry M, Moons L et al. (2008). 
Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods 5: 431-
437. 
 
Castro ME, González-Iriarte M, Barrero AF, Salvador-Tormo N, Muñoz-Chápuli R, Medina, 
MA et al. (2004). Study of puupehenone and related compounds as inhibitors of 
angiogenesis. Int J Cancer 110: 31-38.  
 
Coso S, Bovay E, Petrova TV (2014). Pressing the right buttons: signaling in 
lymphangiogenesis. Blood 123: 2614-2624. 
 
Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). 
Experimental design and analysis and their reporting: new guidance for publication in BJP. 
Br J Pharmacol 172: 3461-71. 
 
Deng Y, Zhang X, Simons M (2015). Molecular controls of lymphatic VEGFR3 signaling. 
Arterioscler Thromb Vasc Biol 35: 421-429. 
 
Detry B, Erpicum C, Paupert J, Blacher S, Maillard C, Bruyère F et al. (2012). Matrix 
metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase. Blood 
119: 5048-5056. 
 
Detry B, Blacher S, Erpicum C, Paupert J, Maertens L, Maillard C et al. (2013) Sunitinib 
inhibits inflammatory corneal lymphangiogenesis. Invest Ophthalmol Vis Sci 54: 3082-3093. 
 
Dietrich T, Bock F, Yuen D, Hos D, Bachmann BO, Zahn G et al. (2010). Cutting edge: 
lymphatic vessels, not blood vessels, primarily mediate immune rejections after 
transplantation. J Immunol 184: 535-539.  
 
  
This article is protected by copyright. All rights reserved. 
Dixelius J, Makinen T, Wirzenius M, Karkkainen MJ, Wernstedt C, Alitalo K et al. (2003). 
Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization 
with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation 
sites. J Biol Chem 278(42): 40973-9. 
 
Dong X, Zhao X, Xiao T, Tian H, Yun C (2011). Endostar, a recombined humanized 
endostatin, inhibits lymphangiogenesis and lymphatic metastasis of lewis lung carcinoma 
xenograft in mice. Thorac Cardiovasc Surg 59: 133-136.  
 
Eklund L1, Bry M, Alitalo K (2013). Mouse models for studying angiogenesis and 
lymphangiogenesis in cancer. Mol Oncol 7: 259-282.  
 
Epstein RJ, Stulting RD, Hendricks RL, Harris DM (1987). Corneal neovascularization 
pathogenesis and inhibition. Cornea 6: 250-257. 
 
García-Caballero M, Marí Beffa M, Cañedo L, Medina MA, Quesada AR (2013). Toluquinol, 
a marine fungus metabolite, is a new angiosuppresor that interferes the Akt pathway. 
Biochem Pharmacol 85: 1727-1740.  
 
Hos D, Schlereth SL, Bock F, Heindl LM, Cursiefen C (2014). Antilymphangiogenic therapy 
to promote transplant survival and to reduce cancer metastasis: what can we learn from the 
eye? Semin Cell Dev Biol 38: 117-130. 
 
Hu J, Ye H, Fu A, Chen X, Wang Y, Chen X et al. (2010). Deguelin - an inhibitor to tumor 
lymphangiogenesis and lymphatic metastasis by downregulation of vascular endothelial cell 
growth factor-D in lung tumor model. Int J Cancer 127: 2455-2466.  
 
Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E et al. (2007). Inhibition of 
cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. 
Cancer Res 67: 10181-10189.  
 
Karaman S, Detmar M (2014). Mechanisms of lymphatic metastasis. J Clin Invest 124: 922-
928. 
 
Khazir J, Riley DL, Pilcher LA, De-Maayer P, Mir BA (2014). Anticancer agents from 
diverse natural sources. Nat Prod Commun 9: 1655-1669.  
 
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: 
Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579. 
 
Le CP, Karnezis T, Achen MG, Stacker SA, Sloan EK (2013). Lymphovascular and neural 
regulation of metastasis: shared tumour signalling pathways and novel therapeutic 
approaches. Best Pract Res Clin Anaesthesiol 27: 409-425. 
 
Lemmon MA, Schlessinger J (2010). Cell signaling by receptor tyrosine kinases. Cell 141: 
1117-1134. 
 
  
This article is protected by copyright. All rights reserved. 
Lenoir B, Wagner DR, Blacher S, Sala-Newby GB, Newby AC, Noel A et al. (2014). Effects 
of adenosine on lymphangiogenesis. PLoS One 9: e92715. 
 
Liang CC, Park AY, Guan JL (2007). In vitro scratch assay: a convenient and inexpensive 
method for analysis of cell migration in vitro. Nat Protoc 2: 329-333. 
 
Liu ZY, Qiu HO, Yuan XJ, Ni YY, Sun JJ, Jing W et al. (2012). Suppression of 
lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-
C and VEGF-D/VEGFR-3 with norcantharidin. Int J Oncol 41: 1762-1772. 
 
Lohela M, Saaristo A, Veikkola T, Alitalo K (2003). Lymphangiogenic growth factors, 
receptors and therapies. Thromb Haemost 90(2): 167-84. 
 
Lohela M, Bry M, Tammela T, Alitalo K (2009). VEGFs and receptors involved in 
angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-65. 
 
Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC et al.  (2001). Isolated 
lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-
C/D receptor VEGFR-3. EMBO J 20: 4762-4773. 
 
Martínez-Poveda B, Rodríguez-Nieto S, García-Caballero M, Medina MA, Quesada AR 
(2012). The antiangiogenic compound aeroplysinin-1 induces apoptosis in endothelial cells 
by activating the mitochondrial pathway. Mar Drugs 10: 2033-2046. 
 
Matsumoto G, Yajima N, Saito H, Nakagami H, Omi Y, Lee U et al. (2010): Cold shock 
domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis 
in a mouse model of squamous cell carcinoma. Clin Exp Metastasis 27: 539-547.  
 
McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL (2010). 
Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J 
Pharmacol 160: 1573-1576.  
 
McGrath JC, McLachlan EM, Zeller R (2015). Transparency in Research involving Animals: 
The Basel Declaration and new principles for reporting research in BJP manuscripts. Br J 
Pharmacol 172: 2427-32.  
 
Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ et al. (2002). Vascular 
permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as 
angiogenesis. J Exp Med 196: 1497-1506. 
 
Nakamura ES, Koizumi K, Kobayashi M, Saiki I (2004). Inhibition of lymphangiogenesis-
related properties of murine lymphatic endothelial cells and lymph node metastasis of lung 
cancer by the matrix metalloproteinase inhibitor MMI270. Cancer Sci 95: 25-31.  
 
Norrmén C, Tammela T, Petrova TV, Alitalo K (2011). Biological basis of therapeutic 
lymphangiogenesis. Circulation 123: 1335-1351. 
  
This article is protected by copyright. All rights reserved. 
 
Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006). VEGF receptor signaling? in 
control of vascular function. Nat Rev Mol Cell Biol 7: 359-371. 
 
Paupert J, Sounni NE, Noël A (2011). Lymphangiogenesis in post-natal tissue remodeling: 
lymphatic endothelial cell connection with its environment. Mol Aspects Med 32: 146-158. 
 
Pepper MS (2001). Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer 
Res 7: 462-468. 
 
Quagliata L, Klusmeier S, Cremers N, Pytowski B, Harvey A, Pettis RJ et al. (2014). 
Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth 
of lymph node metastases in the MT-450 syngeneic rat breast cancer model. Clin Exp 
Metastasis 31: 351-365.  
 
Ribatti D, Crivellato E (2012). "Sprouting angiogenesis", a reappraisal. Dev Biol 372: 157-
165. 
 
Rodríguez-Nieto S, González-Iriarte M, Carmona R, Muñoz-Chápuli R, Medina MA, 
Quesada AR (2002). Antiangiogenic activity of aeroplysinin-1, a brominated compound 
isolated from a marine sponge. Faseb J 16: 261-263. 
 
Schulte-Merker S, Sabine A, Petrova TV (2011). Lymphatic vascular morphogenesis in 
development, physiology, and disease. J Cell Biol 193: 607-618. 
 
Senthilkumar K, Venkatesan J, Manivasagan P, Kim SK (2013). Antiangiogenic effects of 
marine sponge derived compounds on cancer. Environ Toxicol Pharmacol 36: 1097-1108.  
 
Sleeman JP, Thiele W (2009). Tumor metastasis and the lymphatic vasculature. Int J Cancer 
125(12): 2747-56. 
 
Tammela T, Alitalo K (2010). Lymphangiogenesis: Molecular mechanisms and future 
promise. Cell 140: 460-476. 
 
Varricchi G, Granata F, Loffredo S, Genovese A, Marone G (2015). Angiogenesis and 
lymphangiogenesis in inflammatory skin disorders. J Am Acad Dermatol 73(1): 144-53. 
 
Wang J, Guo Y, Zhang BC, Chen ZT, Gao JF (2007). Induction of apoptosis and inhibition of 
cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial 
cells. Pharmacology 80: 207-218. 
 
Wen J, Fu AF, Chen LJ, Xie XJ, Yang GL, Chen XC et al. (2009). Liposomal honokiol 
inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model. Int J 
Cancer 124: 2709-2718.  
 
  
This article is protected by copyright. All rights reserved. 
Witte MH, Dellinger MT, McDonald DM, Nathanson SD, Boccardo FM, Campisi CC et al. 
(2011). Lymphangiogenesis and hemangiogenesis: potential targets for therapy. J Surg Oncol 
103: 489-500. 
 
Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T et al. (2009). Effects 
of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-
type gastric carcinoma model. Br J Cancer 101: 1100-1106.  
 
Zhang L, Zhou F, Han W, Shen B, Luo J, Shibuya M et al. (2010). VEGFR-3 ligand-binding 
and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res 20: 
1319-1331. 
 
Zhang XY, Lu WY (2014). Recent advances in lymphatic targeted drug delivery system for 
tumor metastasis. Cancer Biol Med 11: 247-254. 
 
Zheng W, Aspelund A, Alitalo K (2014). Lymphangiogenic factors, mechanisms, and 
applications. J Clin Invest 124: 878-887. 
 
Zwaans BM, Bielenberg DR (2007). Potential therapeutic strategies for lymphatic metastasis. 
Microvasc Res 74: 145-158. 
 
  
  
This article is protected by copyright. All rights reserved. 
FIGURE LEGENDS 
 
Table 1. Inhibition of zebrafish thoracic duct formation by toluquinol. Thoracic duct 
formation in zebrafish embryos was analyzed to test the in vivo antilymphangiogenic effect of 
toluquinol. The defective thoracic duct formation at 5 dpf was determined by the percentages 
of embryos with severe (no vessel, 0), drastic (5-25 % of normal thoracic duct length), 
moderate (25-90 % of normal thoracic duct length) and no (100% of normal thoracic duct 
length) lymphatic defects. A total of 50 embryos were analyzed in each experimental 
condition. 
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Figure 1. Toluquinol inhibits LEC proliferation and affects LEC viability. 
(A) Chemical structure of toluquinol. 
(B) Representative curve with the dose-dependent effect of toluquinol on the in vitro growth 
of LECs. Cell proliferation is represented as a percentage of untreated cells. Each point 
represents the mean of quadruplicates; SD values were typically lower than 10% of the mean 
values and are omitted for clarity. The half-maximal inhibitory concentration (IC50) value 
was calculated from dose-response curves as the concentration of compound yielding 50% of 
control cell survival. It is expressed as means ± SEM of five independent experiments. 
(C) Percentage of cell viability and cell toxicity after toluquinol treatment for 14, 24, 48 and 
72 h. Results are expressed as the percentage of control (untreated cells) viability and toxicity 
(mean ± SEM of five independent experiments). Controls (100% of viability and 0% 
cytotoxicity) are not represented in each time point for clarity. Mann-Whitney-Wilcoxon test 
was used to decide if the differences among control (untreated cells) and toluquinol-treated 
cells were statistically significant. *P<0.05 versus control.  
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Figure 2. Toluquinol inhibits LEC migration. 
Confluent LEC monolayers were wounded and fresh culture medium was added either in the 
absence or presence of the indicated concentrations of toluquinol. Photographs were taken at 
the beginning of the assay and after 24 and 48 h of incubation. All assays were performed in 
the presence of mitomycin C to avoid a proliferative effect on LEC. 
 
(A) Representative pictures of cell migration. Black drawings in pictures delineate the initial 
(time 0) wound edges (bar=100 μm).  
(B) Quantification of LEC migration. Results are expressed as the percentage of the initial 
wounded area recovered by endothelial cells after 24 or 48 h (mean ± SEM of five 
independent experiments). Mann-Whitney-Wilcoxon test was the test used to analyze if the 
differences among control (untreated cells) and toluquinol-treated cells were statistically 
significant. *P<0.05 versus control. 
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Figure 3. Toluquinol suppresses LEC tubulogenesis. 
LECs were embedded in a collagen gel, maintained in culture for 24 h in order to form tubes, 
and photographed under a phase-contrast microscope. Toluquinol inhibited LEC 
tubulogenesis in a dose-dependent manner at non-toxic doses. 
(A) Representative pictures at different toluquinol concentrations (bar=200 µm). 
(B) Quantification of the tube area density. Values are expressed as mean ± SEM of five 
independent assays and Mann-Whitney-Wilcoxon test was used to evaluate statistically 
significant differences between control (untreated cells) and toluquinol-treated cells. *P<0.05 
versus control. 
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Figure 4. Toluquinol inhibits LEC sprouting from spheroids. 
LEC spheroids embedded in a collagen-methyl cellulose gel extended protrusion sensing the 
environment and formed tube-like structures. Spheroid were treated or not (control) with 
toluquinol. 
(A) Cell sprouting is inhibited by increasing concentrations of toluquinol (bar=100 µm). 
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(B) Graphs correspond to the quantification of (1) the convex envelope area (area of minimal 
convex polygon containing the spheroid core as well as the migrated cells) (left panel) and 
(2) the area occupied by migrating cells (middle panel). The graph at right displays LEC 
density as a function of the distance to the spheroid centre. Values are expressed as mean ± 
SEM of five tests with at least, eight spheroids quantified from each one. Mann-Whitney-
Wilcoxon test was used to decide if the differences among control (untreated spheroids) and 
toluquinol-treated spheroids were statistically significant. *P<0.05 versus control. 
(C) Cells stained in orange with CellTracker Orange CMRA Dye and cells stained in green 
with CellTracker Green CMFDA Dye were mixed in a 1:1 proportion before generating 
spheroids. After 12 h, cell sprouted from spheroids (1: non-treated cells). The treatment of 
mixed spheroids (green + orange cells) with toluquinol during the migration assay led to a 
blockade of cell migration (2: toluquinol treated cells). When LECs were treated with 
toluquinol (5 µM) for 24 h (pretreated LECs), washed with PBS (toluquinol elimination), 
stained in green, mixed with orange untreated cells, and, without toluquinol during the 
migration assay (3: toluquinol pretreated cells), migration occurred in a similar way than in 
control conditions, revealing the reversibility of compound inhibition (bar=100 µm and 50 
µm on higher magnification). 
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Figure 5. Toluquinol induces LEC apoptosis after 14 h of treatment.  
LECs were cultured in the presence of different toluquinol concentrations for 14 h and then 
apoptosis was evaluated by Hoechst staining, flow cytometry and caspase-3/-7 activity. 
(A) Representative pictures showing the effect of toluquinol on nuclei morphology after 
Hoechst staining. The white circles delineate the chromatin condensation of apoptotic nuclei 
(bar=100 µm).  
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(B) Percentage of cells showing chromatin condensation per field. Values are expressed as 
mean ± SEM of the counts evaluated in ten fields from five independent experiments 
(chromatin condensed cells or apoptotic cells were counted by fluorescence microscopy, total 
cells were counted by bright field microscopy).  
(C) Representative histograms showing the effect of toluquinol on LEC cycle distribution. 
After incubation with toluquinol, cells were stained with propidium iodide and percentages of 
subG1, G1 and S/G2/M subpopulations were determined using a MoFlo DakoCytomation 
cytometer.  
(D) Graph corresponds to the distribution of cell subpopulation percentages expressed as 
means ± SEM of five independent assays.  
(E) Effect of toluquinol treatment for 14 h on LEC caspase-3/-7 activity. Results are 
expressed as mean ± SEM of five independent assays.  
(F) Effect of toluquinol 5 µM treatment on LEC caspase-3/-7 activity over the time. 
Results are expressed as mean ± SEM of five independent assays. Controls (caspase-3/-7 
activity=100) are omitted for clarity. 
Statistically significant differences between control (untreated cells) and toluquinol-treated 
cells were determined with the Mann-Whitney-Wilcoxon test. *P<0.05 versus control. . 
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Figure 6. Toluquinol suppresses VEGFR-3 phosphorylation and downstream signaling 
targets. 
After LEC culture in serum-depleted conditions for 24 h, LECs were incubated or not with 
different toluquinol concentrations for 2 hours, and then stimulated for 30 min with VEGF-C 
(A), VEGF-C156S (B) or VEGF-A (C). Cell lysates were collected and Western blotting 
analyses were performed.  
(A) Representative Western blots showing the effects of toluquinol treatment on the 
phosphorylated VEGFR-3, Akt and ERK1/2 in LEC stimulated with VEGF-C (400 ng∙mL-1).  
(B) Illustrative Western blots showing the impact of toluquinol treatment on VEGFR-3, Akt 
and ERK1/2 phosphorylations in LECs stimulated with VEGF-C156S (500 ng∙mL-1).  
(C) Representative Western blots showing the interference of toluquinol treatment on 
VEGFR-2, Akt and ERK1/2 phosphorylations in LECs stimulated with VEGF-A (100 ng∙mL-
1
). 
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Figure 7. Toluquinol inhibits lymphatic outgrowth in mouse lymphatic ring assay. 
Mouse lymphatic duct explants embedded in type I collagen gel were cultured in the absence 
(control) or presence of different doses of toluquinol for 7 days under hypoxic conditions.  
(A) Representative micrographs of lymphatic rings (bar=500 μm). 
(B) For quantification, binarized imaged from 10 rings/condition were subjected to a grid 
corresponding to successive increments at fixed intervals of thoracic duct boundary, and the 
number of microvessel grid intersections (Ni) at Day 7 of incubation was calculated. Values 
are expressed as means ± SEM of ten different rings. The graph (at right) corresponds to 
lymphatic endothelial cell density at a distance (d) = 0.25 mm to the ring border. Mann-
Whitney-Wilcoxon test was used to determine if the differences among control (untreated 
rings) and rings incubated with toluquinol were statistically significant. *P<0.05 versus 
control. 
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Figure 8. Toluquinol blocks thoracic duct development in zebrafish model. 
Transgenic Fli1:eGFPy1 zebrafish embryos were incubated in zebrafish water with the 
indicated concentrations of the tested compound at 28.5°C for 4 days and then, thoracic duct 
length was analyzed in the anesthetized embryos.  
(A) Schematic drawing of a 5 days post-fertilization (dpf) zebrafish embryo with the main 
anatomical features. Abbreviations used on this drawing denote: dorsal longitudinal 
anastomotic vessels (DLAV), thoracic duct (TD), dorsal artery (DA), posterior cardinal vein 
(PCV), parachordal line (PAC), intersegmental vessels (ISV), arterial intersegmental vessels 
(aISV), venous intersegmental vessels (vISV), and intersegmental lymphatic vessels (ISLV). 
(B) Representative pictures of untreated and treated zebrafishes are shown. Zebrafish thoracic 
duct is indicated with white arrowheads on higher magnification pictures and it is included in 
white rectangles on lower magnification pictures. Abbreviations indicate the main zebrafish 
embryo anatomical structures (bar=100 μm and 70 µm on higher magnification).  
(C) Quantification of the defective thoracic duct formation at 5 dpf determined by the 
percentages of embryos with severe, drastic, moderate and no, lymphatic defects, expressed 
as the percentage of thoracic duct length. A total of 50 embryos were analyzed in each 
experimental condition. 
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Figure 9. Toluquinol impairs the in vivo VEGF-C-stimulated lymphangiogenesis in the 
mouse ear collagen sponges. 
Gelatin sponges were soaked with either DMEM containing the vehicle (DMSO) as negative 
control, or VEGF-C (1 µg∙mL-1) as positive control or VEGF-C and different concentrations 
of toluquinol, (indicated with “T” in the graphs). Sponges were implanted between the two 
skin’s layers of ear’s mice for 3 weeks.  
(A) Lymphatic and blood vasculatures were examined by LYVE-1 (green) and CD31 (red) 
immunostainings, respectively. Dapi staining was used to detect cell nuclei (blue) (bars=1500 
µm and 500 µm on higher magnification). 
(B) The graphs represent the computerized quantification of the lymphatic (left panel) or 
blood (middle panel) vessel area densities, defined as the area occupied by vessels divided by 
the area of sponge section. Data are expressed as means ± SEM of 5 mice. The right graph 
corresponds to vessel distribution from the sponge edge to its center. The arrows indicated 
the maximal distance of LEC migration (Lmax). Mann- Whitney-Wilcoxon test was used to 
evaluate statistically significant differences between sponges soaked with VEGF-
C+toluquinol and control sponges with VEGF-C. *P<0.05 versus VEGF-C-stimulated 
sponges.   
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Figure 10. Toluquinol reduces the corneal neovascularization in cauterized mouse corneas.  
Corneal lymph/angiogenesis was induced by thermal cauterization and mice were daily i.p. 
administered with 75 nmol of toluquinol (treated mice) or PBS (control mice).  Corneas were 
flat-mounted at Day 9 post-injury and immunostained for detecting lymphatic vessels 
(LYVE-1 positive, in green) and blood vessels (CD31 positive, in red). Whole mounted 
corneas were observed under a fluorescent (A-D) or a confocal (E-F) microscope.  
 
(A-D) Representative pictures of corneas from non-treated (A,B) and treated (C,D) mice. 
Lymphatic vessels and blood vessels appear in green and in red, respectively (bars=1000 µm 
in A and C; 500 µm in B and C). 
  
This article is protected by copyright. All rights reserved. 
 
(E-F) Representative pictures of filopodia-like structures (white arrowheads) displayed by 
migrating LECs in corneas from control (E) and toluquinol-treated mice (F) (bars =10 µm).  
 
(G-H) Computer-assisted quantification was based on the splitting of green and red channel 
to dissociate lymphatic from blood networks. The vessel area (area covered by neoformed 
vessels), total length (cumulative length of the vessels), branching (number of bifurcations) 
and end-point (number of sprout tips) densities were calculated after image binarization. All 
results were divided by the total cornea area. Results are expressed as the mean ± SEM of 15 
mice.  
 
(I) A grid was applied on each cornea picture to establish the distribution curves of capillaries 
around the limbal vessels and it is represented as the number of intersections (Ni) versus the 
distance to the limbus.  
 
(J) Graphs represent the number (left) and length (right) of filopodia-like structures in a total 
length of 25 µm at the end of the lymphatic vessel. For these quantifications, 10 pictures were 
quantified per mouse and corneas from 5 mice were evaluated.  
 
Mann-Whitney-Wilcoxon test was the statistical test used to evaluate significant differences 
between control mice (PBS) and toluquinol-injected mice. *P<0.05 versus control mice.   
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 TABLES OF LINKS - LIGANDS  
 
 
LIGAN
DS 
   
Ligand 
name 
Ligand Id (insert after the standard URL below, no spaces) INN 
only 
IUP
AC 
Nam
e 
VEGF-
C 
http://www.guidetopharmacology.org/GRAC/LigandDisplayFo
rward?ligandId=5087 
VEGF-
C 
 
VEGF-
A 
http://www.guidetopharmacology.org/GRAC/LigandDisplayFo
rward?ligandId=5085 
VEGF-
A 
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VEGF-
C156S 
Not found   
Mitomy
cin 
http://www.guidetopharmacology.org/GRAC/LigandDisplayFo
rward?ligandId=7089 
Mitomy
cin 
 
Toluqui
nol 
Not found   
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